List of Natioanl Advisory Group Recommendations since ...

The submitting company's justification of the treatment's cost in relation to its health benefits was not sufficient to gain acceptance by SMC Not recommended Lack of evidence of economic benefits. SMC bevacizumab (Avastin) March 2013. 719/11 abatacept 250mg powder for concentrate for solution for infusion (Orencia®) ................
................